Patterns of Radiotherapy Practice for Pancreatic Cancer in Japan: Results of the Japanese Radiation Oncology Study Group (JROSG) Survey
- Department of Radiology, University of the Ryukyus, Okinawa (Japan)
- Department of Radiation Oncology, National Cancer Center, Tokyo (Japan)
- Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital, Tokyo (Japan)
- Department of Radiation Oncology, Tohoku University, Sendai (Japan)
- Department of Radiology, Yamanashi University, Yamanashi (Japan)
- Department of Radiation Oncology, Saitama Cancer Center, Saitama (Japan)
- Department of Radiation Oncology and Image-Applied Therapy, Kyoto University, Kyoto (Japan)
- Department of Radiology, Tokyo Medical and Dental University, Tokyo (Japan)
- Department of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe (Japan)
- Department of Radiation Oncology, Sapporo Kosei General Hospital, Sapporo (Japan)
- Department of Radiology, Kurume University, Kurume (Japan)
- Department of Radiation Oncology, Shimane Medical University, Shimane (Japan)
- Department of Radiation Oncology, Juntendo University, Tokyo (Japan)
- Department of Radiation Oncology, Yamagata University, Yamagata (Japan)
- Department of Radiation Oncology, Kinki University School of Medicine, Osaka (Japan)
Purpose: To determine the patterns of radiotherapy practice for pancreatic cancer in Japan. Methods and Materials: A questionnaire-based national survey of radiotherapy for pancreatic cancer treated between 2000 and 2006 was conducted by the Japanese Radiation Oncology Study Group (JROSG). Detailed information on 870 patients from 34 radiation oncology institutions was accumulated. Results: The median age of all patients was 64 years (range, 36-88), and 80.2% of the patients had good performance status. More than 85% of patients had clinical Stage T3-T4 disease, and 68.9% of patients had unresectable disease at diagnosis. Concerning radiotherapy (RT), 49.8% of patients were treated with radical external beam RT (EBRT) (median dose, 50.4 Gy), 44.4% of patients were treated with intraoperative RT (median dose, 25 Gy) with or without EBRT (median dose, 45 Gy), and 5.9% of patients were treated with postoperative radiotherapy (median dose, 50 Gy). The treatment field consisted of the primary tumor (bed) only in 55.6% of the patients. Computed tomography-based treatment planning and conformal RT was used in 93.1% and 83.1% of the patients treated with EBRT, respectively. Chemotherapy was used for 691 patients (79.4%; before RT for 66 patients; during RT for 531; and after RT for 364). Gemcitabine was the most frequently used drug, followed by 5-fluorouracil. Conclusion: This study describes the general patterns of RT practice for pancreatic cancer in Japan. Most patients had advanced unresectable disease, and radical EBRT, as well as intraoperative RT with or without EBRT, was frequently used. Chemotherapy with gemcitabine was commonly used in conjunction with RT during the survey period.
- OSTI ID:
- 21436032
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 77, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2009.05.063; PII: S0360-3016 (09)00926-2; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Concurrent Radiotherapy and Gemcitabine for Unresectable Pancreatic Adenocarcinoma: Impact of Adjuvant Chemotherapy on Survival
Radiation Therapy With Full-Dose Gemcitabine and Oxaliplatin for Unresectable Pancreatic Cancer